Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises FJ Dynamics on its acquisition of Sveaverken Svea Agri
Mandate

Vinge advises FJ Dynamics on its acquisition of Sveaverken Svea Agri

October 16, 2019 M&A

Vinge has advised FJ Dynamics, a leading global robotic company in the agricultural sector, in connection with its acquisition of Sveaverken Svea Agri.

Sveaverken Svea Agri is an animal farming company with over 100 years history with headquarters in Sweden. With the acquisition, FJ Dynamics will empower traditional animal farming with leading intelligent robotics and create significant value and synergy to benefit more customers around the world.

Vinge’s team consisted of, among others, Ulrich Ziche, Qun Gu, Desirée Sjöblom and Jesper Lindvall (M&A and commercial agreements), Morgan Hallén and Daniel Lennartsson Anderås (Banking, financing and restructuring), Sophia Holm (Employment) and Anne Wijkman (Real Estate and lease agreements).
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024